Newsroom

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Feb. 1, 2018– AVEO Oncology (NASDAQ: AVEO) today announced the appointment of John H. Johnson to the Company’s Board of Directors. Mr. Johnson brings to AVEO over three decades of experience in the biotechnology and pharmaceuticals industries, having held commercial and executive management roles at leading global corporations that have a focus on oncology, including Johnson &

Download PDF Poster Presentation Delivered at the 2018 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 19, 2018– AVEO Oncology (NASDAQ:AVEO) today announced the presentation of data from a multicenter, Phase 1b/2 study of FOTIVDA® (tivozanib), a potent, selective, long half-life inhibitor of all three vascular endothelial growth factor (VEGF) receptors, in patients with advanced,

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 4, 2018– AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 11, 2018 at 11:30 a.m. Pacific Time. A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of

Download PDF Provides Approximately $12.1M in Additional Cash Flow Over 2018-19 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 2, 2018– AVEO Oncology (NASDAQ:AVEO) today announced that it has completed the refinancing of its existing $20.0 million debt facility with Hercules Capital, Inc. and its affiliates, the terms of which enable approximately an additional $12.1 million in cash flow over 2018 and 2019, when compared to the prior loan. The

Download PDF – Enrollment complete in Phase 2 portion of Phase 1/2 TiNivo trial;Next data presentation expected at 2018 Genitourinary Cancers Symposium in February 2018- – Investigator-sponsored studies of ficlatuzumab initiated in HNSCC and Pancreatic Cancer – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dec. 7, 2017– AVEO Oncology (NASDAQ:AVEO) today announced clinical updates for two of its oncology programs: FOTIVDA® (tivozanib), the Company’s

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 20, 2017– AVEO Oncology (NASDAQ: AVEO) today announced the appointment of Nikhil Mehta, Ph.D., as Senior Vice President of Regulatory and Quality Assurance, effective November 20, 2017. In this role, Dr. Mehta will oversee all aspects of regulatory, quality and technical operations for the company’s portfolio. Dr. Mehta brings to AVEO more than 25 years of experience

Download PDF HEMEL HEMPSTEAD, England & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 15, 2017– EUSA Pharma and AVEO Oncology (NASDAQ:AVEO) today announced the first commercial launch of FOTIVDA® (tivozanib) with the initiation of product sales in Germany. In the European Union, Norway and Iceland, tivozanib is indicated for the first line treatment of adult patients with advanced renal cell carcinoma (aRCC) and for adult patients who are vascular

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 8, 2017– AVEO Oncology (NASDAQ: AVEO) today announced that Michael Bailey, president and chief executive officer, will be presenting at the following investor conferences: A live webcast of the presentations can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the webcast will be archived for 30 days